Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PALLADONE vs ANEXSIA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Agonist at mu-opioid receptors, modulating pain perception via central and peripheral pathways.
ANEXSIA is a combination of hydrocodone and acetaminophen. Hydrocodone is an opioid agonist that binds to mu-opioid receptors in the central nervous system, altering pain perception and emotional response to pain. Acetaminophen's analgesic mechanism is not fully understood but involves inhibition of COX enzymes in the CNS and modulation of descending serotonergic pathways.
Management of moderate to severe pain requiring daily opioid treatment
Relief of moderate to moderately severe pain
Immediate-release: 4-8 mg orally every 4-6 hours as needed for pain; extended-release: 8 mg orally every 12 hours, titrated based on response and tolerance.
50-100 mg orally every 4-6 hours as needed; maximum 400 mg/day.
Terminal elimination half-life is approximately 18 hours (range 12-24 h); supports extended dosing intervals.
Terminal elimination half-life is 4-6 hours in adults with normal renal function; prolonged to 12-24 hours in severe renal impairment (Cr Cl <30 m L/min).
Hepatic via CYP3A4 and CYP2D6 to active metabolite hydromorphone; also via glucuronidation.
Hydrocodone is metabolized via CYP2D6 and CYP3A4 to hydromorphone and norhydrocodone. Acetaminophen is primarily metabolized via hepatic glucuronidation and sulfation; a minor pathway via CYP2E1 produces NAPQI, which is detoxified by glutathione.
Primarily renal (90%) as unchanged drug and glucuronide conjugate; ~10% biliary/fecal.
Approximately 70% renal (unchanged drug and metabolites), 20% biliary/fecal, 10% other.
Approximately 95-99% bound to albumin and alpha-1-acid glycoprotein.
Approximately 95% bound to plasma albumin and alpha-1-acid glycoprotein.
Vd ~4 L/kg (range 2-6 L/kg). Large Vd indicates extensive tissue distribution.
0.2-0.4 L/kg, indicating limited extravascular distribution primarily confined to plasma and interstitial fluid.
Oral: ~40% (range 20-60%) due to first-pass metabolism; rectal: similar to oral.
Oral: 80-90%; Intramuscular: 90-100%; Rectal: 70-80%.
For Cr Cl 30-59 m L/min: start with 50% of recommended dose and titrate cautiously; for Cr Cl <30 m L/min: not recommended.
GFR 30-89 m L/min: no adjustment; GFR 15-29 m L/min: 50% dose reduction; GFR <15 m L/min: avoid use.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: start at 50% of usual dose and monitor; Child-Pugh Class C: not recommended.
Child-Pugh A: no adjustment; Child-Pugh B: 50% dose reduction; Child-Pugh C: avoid use.
Weight-based dosing: 0.1-0.2 mg/kg orally every 4-6 hours as needed (immediate-release); maximum single dose 5 mg. Extended-release not recommended in children.
1-2 mg/kg/dose orally every 6 hours; maximum 6 mg/kg/day.
Start at the low end of dosing range (e.g., 2-4 mg immediate-release every 4-6 hours) and titrate slowly; monitor for increased sensitivity and respiratory depression.
Initiate at 25 mg every 6 hours; increase cautiously; monitor renal function.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; interaction with alcohol and CNS depressants.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; hepatotoxicity from acetaminophen.
Respiratory depression,Addiction and abuse potential,Risks from concomitant use of benzodiazepines or other CNS depressants,Neonatal opioid withdrawal syndrome,Adrenal insufficiency,Severe hypotension,Seizures,Serotonin syndrome with serotonergic drugs
Risk of respiratory depression, especially in elderly or debilitated patients; adrenal insufficiency; severe hypotension; seizures; opioid-induced hyperalgesia; acetaminophen hepatotoxicity (avoid exceeding 4 g/day); serotonin syndrome if used with serotonergic agents.
Significant respiratory depression,Acute or severe bronchial asthma,Known or suspected gastrointestinal obstruction,Hypersensitivity to hydromorphone or any component,Concurrent use of MAOIs or within 14 days
Hypersensitivity to hydrocodone or acetaminophen; significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting; known or suspected GI obstruction; severe hepatic impairment; concomitant use of MAOIs or within 14 days.
Avoid grapefruit juice as it may increase hydromorphone levels. Avoid alcohol in any form (including beverages, cooking wines, and medications containing alcohol) due to risk of additive CNS depression and respiratory depression. High-fat meals may delay absorption; take consistently with or without food to maintain stable effects.
Avoid alcohol; may increase risk of hepatotoxicity and GI bleeding. Limit caffeine intake from coffee, tea, cola, or energy drinks due to added caffeine content. High-fat meals may delay absorption; take on empty stomach for faster onset if tolerated.
PALLADONE (hydromorphone) is an opioid agonist. Data in pregnancy are limited. First trimester: Use is associated with a small risk of congenital malformations, particularly neural tube defects, based on some epidemiologic studies; however, absolute risk is low. Second and third trimesters: Chronic use may lead to fetal dependence and neonatal opioid withdrawal syndrome (NOWS) after delivery. Additionally, use near term may cause neonatal respiratory depression, and use during labor may prolong labor.
First trimester: Data are limited; no increased risk of major malformations reported in small studies. Second and third trimesters: Associated with premature closure of the ductus arteriosus and oligohydramnios due to fetal renal effects; avoid use after 30 weeks gestation.
Hydromorphone is excreted into breast milk. The milk-to-plasma (M/P) ratio is approximately 0.65. The estimated infant dose via breast milk is about 0.5-1% of the maternal weight-adjusted dose. While generally considered compatible with breastfeeding at low maternal doses, caution is advised; monitor infant for excessive drowsiness, respiratory depression, and feeding difficulties. Avoid use in mothers with high-dose or prolonged therapy.
Excreted into breast milk in low concentrations (M/P ratio not established). Not recommended during breastfeeding due to potential for adverse effects in the infant, including renal impairment and gastrointestinal bleeding.
Pregnancy may alter pharmacokinetics of hydromorphone: increased clearance and volume of distribution may reduce serum concentrations. Dose adjustments may be necessary to maintain analgesic efficacy. Close monitoring for breakthrough pain and signs of withdrawal is recommended. Due to lack of robust data, titrate dose based on clinical response and maternal safety, using the lowest effective dose. Avoid abrupt discontinuation to prevent withdrawal.
Dose adjustment not generally required; however, due to increased renal clearance in pregnancy, shortened dosing intervals may be necessary for sustained efficacy. Use lowest effective dose for shortest duration.
PALLADONE (hydromorphone extended-release) is a potent mu-opioid agonist. Do not crush or allow patients to chew capsules; this can cause rapid release and fatal overdose. Use with extreme caution in patients with respiratory compromise, COPD, or sleep apnea. Initiate at the lowest effective dose and titrate slowly. Monitor for constipation and prescribe a bowel regimen prophylactically. Consider naloxone co-prescription for high-risk patients. Avoid use in patients with paralytic ileus or suspected GI obstruction. Renal impairment requires dose adjustment due to accumulation of hydromorphone-3-glucuronide.
ANEXSIA is a combination analgesic containing paracetamol, ibuprofen, and caffeine. It is contraindicated in patients with active peptic ulcer disease, severe hepatic impairment, or hypersensitivity to NSAIDs. Avoid concurrent use with other NSAIDs or paracetamol-containing products. Monitor renal function in elderly or dehydrated patients. Caffeine may exacerbate anxiety or insomnia.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Swallow capsules whole; do not crush, chew, or dissolve them as this can cause a fatal overdose.,Avoid alcohol and any medications containing alcohol while taking this drug as it increases risk of dangerous side effects.,Do not drive or operate heavy machinery until you know how PALLADONE affects you; it may cause dizziness or drowsiness.,This medication carries a risk of addiction, abuse, and misuse; store it securely out of reach of others.,Report any difficulty breathing, extreme drowsiness, confusion, or signs of allergic reaction immediately.,Do not stop suddenly; your doctor will help you taper off to prevent withdrawal symptoms.,Constipation is common; increase fluid and fiber intake and use laxatives as recommended by your doctor.
Do not exceed recommended dose; overdosage of paracetamol can cause liver damage.,Take with food or milk to reduce gastrointestinal upset.,Avoid alcohol while taking this medication to reduce risk of liver toxicity and GI bleeding.,Discontinue use and consult if signs of allergic reaction, GI bleeding, or liver problems occur.,Caffeine may cause nervousness, insomnia, or increased heart rate; limit caffeine-containing foods and beverages.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PALLADONE vs ANEXSIA, answered by our medical review team.
PALLADONE is a Opioid Analgesic that works by Agonist at mu-opioid receptors, modulating pain perception via central and peripheral pathways.. ANEXSIA is a Opioid Analgesic Combination that works by ANEXSIA is a combination of hydrocodone and acetaminophen. Hydrocodone is an opioid agonist that binds to mu-opioid receptors in the central nervous system, altering pain perception and emotional response to pain. Acetaminophen's analgesic mechanism is not fully understood but involves inhibition of COX enzymes in the CNS and modulation of descending serotonergic pathways.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PALLADONE and ANEXSIA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PALLADONE is: Immediate-release: 4-8 mg orally every 4-6 hours as needed for pain; extended-release: 8 mg orally every 12 hours, titrated based on response and tolerance.. The standard adult dose of ANEXSIA is: 50-100 mg orally every 4-6 hours as needed; maximum 400 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PALLADONE and ANEXSIA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PALLADONE is classified as Category C. PALLADONE (hydromorphone) is an opioid agonist. Data in pregnancy are limited. First trimester: Use is associated with a small risk of congenital malformations, particularly neural. ANEXSIA is classified as Category C. First trimester: Data are limited; no increased risk of major malformations reported in small studies. Second and third trimesters: Associated with premature closure of the ductus . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.